

ASX Announcement

Distinguished Oncologist Professor Daniel Von Hoff Joins Race Oncology as a Clinical Consultant

- Eminent Professor Dr Daniel Von Hoff joins Race Oncology's Clinical Advisory Board to advise on the clinical development of RC220 bisantrene
- Prof Von Hoff is a world leading expert in early clinical trials and translational research with extensive personal clinical experience using bisantrene
- Appointment provides Race with a rich insight into the historical use of bisantrene and valuable experience to aid the clinical development of RC220 bisantrene.

2 July 2024 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Professor Daniel Von Hoff to Race’s Clinical Advisory Board. Dr Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is a eminent physician and is the Executive Vice President of the Molecular Medicine Divisions and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona and City of Hope¹. He also holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at Honor Health Clinical Research Institute and Professorship of Medicine at the Mayo Clinic.

Dr. Von Hoff is a pioneering world leader in translational medicine, accelerating novel drug discoveries from the laboratory to cancer treatments in clinical trials, where he has been involved in over 300 clinical studies. Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory.

Early in his career, Dr Von Hoff worked with the original developers of bisantrene, Lederle Laboratories, in the design and execution of the clinical studies of bisantrene. He has authored more than 10 publications on bisantrene, including the Phase 3 breast cancer study where bisantrene was compared to doxorubicin and mitoxantrone². Dr Von Hoff and his colleagues have contributed to the development of many US Food and Drug Administration (FDA) approved pharmaceuticals in routine use, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and pexidartinib. He has a strong interest in early-phase clinical trials where he and his colleagues are currently focused on developing novel therapies for patients with advanced pancreatic cancer.

Professor Von Hoff has published more than 795 papers, 143 book chapters, over 1195 abstracts with an h-index of 127. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO) for his outstanding contributions to cancer research leading to significant improvement in patient care, and he was named one of the ASCO 50 Oncology Luminaries in 2014. Most recently, he received the American Association of Cancer Research (AACR) Distinguished Public Service Award in recognition of his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators.

Professor Daniel Von Hoff comments: *“I am very pleased to be joining the Race Oncology team as an advisor to help in the further development of the reformulated bisantrene (RC220). It is great to see this important follow up on a molecule which has previously demonstrated clinical activity against leukaemia and solid cancers.”*

Race Chief Executive Officer, Dr Daniel Tillett comments: *“To attract the interest of a clinical researcher of the international calibre of Professor Von Hoff to counsel Race is humbling. I have no doubt that his expertise and experience will accelerate our clinical and commercial development of RC220 bisantrene.”*

1. <https://www.aacr.org/professionals/membership/aacr-academy/fellows/daniel-d-von-hoff-md/>

2. Cowan, J. D. et al. *Randomized Trial of Doxorubicin, Bisantrone, and Mitoxantrone in Advanced Breast Cancer: A Southwest Oncology Group Study*. JNCI: J. Natl. Cancer Inst. 83, 1077–1084 (1991).

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrone has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 bisantrene as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au